Wie hoch ist der Preis für DICE Therapeutics, Inc. (DICE)

Preis für DICE Therapeutics, Inc. (DICE) ist $47.55

Wie hoch ist die Marktkapitalisierung für DICE Therapeutics, Inc. (DICE)

Marktkapitalisierung für DICE Therapeutics, Inc. (DICE) ist $1.10B

DICE Therapeutics, Inc. (DICE) Aktiensplits

DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics. Their flagship therapeutic asset is DC-806, an orally administered antagonist designed to inhibit interleukin-17, a pivotal pro-inflammatory signaling molecule widely recognized as a validated target across numerous immunology indications. Furthermore, DICE is advancing other oral treatment options, including therapies aimed at the α4β7 integrin for the management of inflammatory bowel diseases, and compounds targeting the αVβ1/αVβ6 integrin to treat idiopathic pulmonary fibrosis. Beyond these areas, the company also dedicates efforts to immuno-oncology, specifically developing antibody-based therapeutics. Established in 2013, DICE Therapeutics is headquartered in South San Francisco, California.